Basilea’s Toctino (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids, has obtained regulatory approval from Health Canada. Toctino has
The expanded facility has been fully validated, and will continue to deliver the same high-quality Sensititre products, including the Sensititre microbroth dilution plates used in clinical and veterinary
ARYx Therapeutics has announced the review of the results of the Phase 2b clinical trial, PASCAL, testing the efficacy and safety of ARYx’s compound for the treatment of
India-based Kunnath Pharmaceuticals is seeking new license to manufacture its Musli Power Xtra with a formula including Safed Musli. The company has approached Ayurvedic Drug Control office in
Bafna Pharmaceuticals has received approval from Sri Lankan authorities for the launch of Olmesartan Medoxomil, anti-hypertension drug. The drug will be launched as Olmebaf, and will initiate marketing
Bayer MaterialScience has entered into an agreement to acquire PolyBioMed based in Sheffield, UK, thereby expanding its product portfolio for medical technology PolyBioMed, a subsidiary of Lombard Medical
Pfizer has submitted pediatric data for Lipitor (atorvastatin) to the EMEA. Reportedly, Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5mg dose, which
The company said that the application covers an implantable medical device useful in re-directing the immune system to stop tissue inflammation. The company claims that the essence of
Evotec has been granted up to E2.5m in research funds from the BMBF, within the Neu2 consortium, to advance research and development activities on the target Serine Racemase
Under these licensing agreements, EraGen will have access to Illumina’s BeadXpress platform for the continued development and commercialisation of molecular-based, high-throughput clinical multiplexed assays with its unique, patented
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.